Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.1%

5 terminated/withdrawn out of 31 trials

Success Rate

73.7%

-12.8% vs industry average

Late-Stage Pipeline

16%

5 trials in Phase 3/4

Results Transparency

21%

3 of 14 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

14(45.2%)

Phase 1

11(35.5%)

Phase 3

5(16.1%)

Early Phase 1

1(3.2%)

31Total

Phase 2(14)

Phase 1(11)

Phase 3(5)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials

NCT00736450Early Phase 1Terminated

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT01064713Phase 2Completed

Phase II Study of Tesetaxel in Metastatic Melanoma

Role: collaborator

NCT00836173Phase 2Withdrawn

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT01200342Phase 2Terminated

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Role: collaborator

NCT00017589Phase 2Completed

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Role: lead

NCT00016263Phase 3Completed

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Role: lead

NCT00030641Phase 2Unknown

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Role: lead

NCT00024440Phase 3Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Role: lead

NCT00017602Phase 3Completed

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT01296243Phase 2Unknown

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Role: lead

NCT01170975Phase 1Completed

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

Role: lead

NCT01573468Phase 2Unknown

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

Role: lead

NCT01221870Phase 2Unknown

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Role: lead

NCT01315431Phase 1Unknown

A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

Role: lead

NCT01215877Phase 2Unknown

Tesetaxel for Previously Treated Patients With Bladder Cancer

Role: lead

NCT01609127Phase 2Unknown

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT00636545Phase 1Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Role: lead

NCT01095120Phase 2Unknown

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Role: lead

NCT01348009Phase 1Unknown

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Role: lead

NCT00543075Phase 1Completed

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Role: lead